Vertex Pharmaceuticals, Inc’s recent filing unveils that its EVP, Chief Reg. & Quality Off. Tatsis Ourania unloaded Company’s shares for reported $2.14 million on Jan 07 ’26. In the deal valued at $474.99 per share,4,500 shares were sold. As a result of this transaction, Tatsis Ourania now holds 42,293 shares worth roughly $19.81 million.
Then, WAGNER CHARLES F JR sold 9,532 shares, generating $4,394,252 in total proceeds. Upon selling the shares at $461.00, the EVP, CO & FO now owns 37,725 shares.
Before that, Tatsis Ourania bought 4,500 shares. Vertex Pharmaceuticals, Inc shares valued at $2,137,455 were divested by the Officer at a price of $474.99 per share.
RBC Capital Mkts upgraded its Vertex Pharmaceuticals, Inc [VRTX] rating to an Outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Bernstein’s analysts, who increased its forecast for the stock in mid January from “a Mkt perform” to “an Outperform”. Wolfe Research revised its rating on January 06, 2026. It rated VRTX as “an Outperform” which previously was an “a Peer perform”.
Price Performance Review of VRTX
On Friday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock jump 0.23% to $468.41. Over the last five days, the stock has gained 6.72%. Vertex Pharmaceuticals, Inc shares have risen nearly 9.44% since the year began. Nevertheless, the stocks have risen 3.32% over the past one year.
How much short interest is there in Vertex Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2025-12-31, growing by 0.57 million shares to a total of 5.02 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-28 was 4.46 million shares. There was a rise of 11.29%, which implies that there is a positive sentiment for the stock.
